Besides exhibiting a dominant-negative activity that obstructs wild-type p53 functions, mutations in p53 can also acquire oncogenic activity by gain-of-function (GOF) mechanisms in which the mutant protein interact with novel transcription factors or cofactors to regulate gene transcription and expression to drive cancer development (Figure 4) 24. This evidence concerns the gene TP53 and cancer.